Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teniposide
- Development stage
- Phase 4
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Teniposide is a semisynthetic derivative of podophyllotoxin and belongs to the class of topoisomerase II inhibitors. It is primarily used in combination with other chemotherapy agents for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in children. Teniposide acts as a phase-specific cytotoxic agent, targeting cells in the late S or early G2 phase of the cell cycle and preventing them from entering mitosis. Its mechanism involves inhibition of DNA topoisomerase II, leading to single and double-stranded DNA breaks and DNA-protein cross-links, ultimately resulting in cell death. Teniposide does not intercalate into or bind strongly to DNA but stabilizes the topoisomerase II-DNA complex, increasing cytotoxicity through accumulation of double-stranded breaks[1][3][4][5][7].
- Brand names
- Vumon
- Other names
- teniposide4-demethylepipodophyllotoxin 9-[4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside]
02
Targets
TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on teniposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teniposide.